Skip Navigation

Cardiovascular Research 2002 53(4):902-910; doi:10.1016/S0008-6363(01)00531-4
© 2002 by European Society of Cardiology
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Liao, Z.
Right arrow Articles by Latchman, D. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Liao, Z.
Right arrow Articles by Latchman, D. S.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Copyright © 2002, European Society of Cardiology

Cardiotrophin-1 (CT-1) can protect the adult heart from injury when added both prior to ischaemia and at reperfusion

Zhihong Liaoa,1, Bhawanjit K. Brara,1, Qing Caib, Anastasis Stephanoua, Rhona M. O'Learyc, Diane Pennicad, Derek M. Yellonb and David S. Latchmana,*

aInstitute of Child Health, University College London, 30 Guilford Street, London WC1N 1EH, UK
bHatter Institute of Cardiology, University College Hospitals, London, UK
cDepartment of Protein Sciences, Genentech Inc., South San Francisco, CA, USA
dDepartment of Molecular Oncology, Genentech Inc., South San Francisco, CA, USA

* Corresponding author. Tel.: +44-20-7905-2189; fax: +44-20-7242-8437 d.latchman{at}ich.ucl.ac.uk

Objectives: To determine whether the cytokine cardiotrophin-1 (CT-1) can protect the adult heart against ischaemia/reperfusion when added either prior to ischaemia or at reperfusion. Background: CT-1 has previously been shown to protect cultured embryonic or neonatal cardiocytes from cell death. To assess the therapeutic potential of CT-1, it is necessary to determine whether this effect can be observed in adult cardiac cells both in culture and most importantly in the intact heart. Methods: We examined the protective effect of CT-1 both in cultured adult rat cardiocytes and in the rat intact heart. In both cases, the cardiac cells were exposed to hypoxia/ischaemia followed by reoxygenation/reperfusion and CT-1 was administered either prior to hypoxia/ischaemia or at reoxygenation/reperfusion. Results: CT-1 has a protective effect in reducing ischaemic damage in the intact heart ex vivo as assayed by infarct size to area at risk ratio (20% compared to 35%). Similar protective effects against cell death were noted in adult cells in vitro. Both in vitro and ex vivo CT-1 can exert a protective effect when added at the time of reoxygenation/reperfusion as well as prior to the hypoxic/ischaemic stimulus (cell death reduced from 50 to 20% in TUNEL assay, infarct size to zone at risk ratio reduced from 35 to 20%). These protective effects are blocked by an inhibitor of the p42/p44 MAPK pathway. Conclusion: CT-1 can protect adult cardiac cells both in vitro and in vivo when added both prior to or after the hypoxic/ischaemic stimulus. The potential therapeutic benefit of CT-1 when added at the time of reperfusion following ischaemic damage is discussed.

Condensed abstract

The cytokine cardiotrophin-1 (CT-1) has previously been shown to have protective effects in embryonic or neonatal cardiac cells in culture. Here we show for the first time that CT-1 can protect adult cardiac cells both in culture and in the intact heart exposed to ischaemia/reperfusion. Moreover, this protective effect can be observed when CT-1 is added at reperfusion after ischaemia as well as prior to ischaemia. The ability of CT-1 to protect the intact adult heart when given at reperfusion suggests it may have therapeutic potential in the clinical situation.

KEYWORDS Apoptosis; Cytokines; Hypoxia/anoxia; Reperfusion


1 These authors contributed equally to the work.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
J. Biol. Chem.Home page
T. Miyake, N. S. Alli, A. Aziz, J. Knudson, P. Fernando, L. A. Megeney, and J. C. McDermott
Cardiotrophin-1 Maintains the Undifferentiated State in Skeletal Myoblasts
J. Biol. Chem., July 17, 2009; 284(29): 19679 - 19693.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
D. J. Hausenloy and D. M. Yellon
Cardioprotective growth factors
Cardiovasc Res, July 15, 2009; 83(2): 179 - 194.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
N. Lopez, N. Varo, J. Diez, and M. A. Fortuno
Loss of myocardial LIF receptor in experimental heart failure reduces cardiotrophin-1 cytoprotection. A role for neurohumoral agonists?
Cardiovasc Res, August 1, 2007; 75(3): 536 - 545.
[Abstract] [Full Text] [PDF]


Home page
Arch SurgHome page
D. W. Ho, Z. F. Yang, C. K. Lau, K. H. Tam, J. Y. To, R. T. Poon, and S. T. Fan
Therapeutic Potential of Cardiotrophin 1 in Fulminant Hepatic Failure: Dual Roles in Antiapoptosis and Cell Repair
Arch Surg, November 1, 2006; 141(11): 1077 - 1084.
[Abstract] [Full Text] [PDF]


Home page
J. Cell Sci.Home page
B. Ateghang, M. Wartenberg, M. Gassmann, and H. Sauer
Regulation of cardiotrophin-1 expression in mouse embryonic stem cells by HIF-1{alpha} and intracellular reactive oxygen species
J. Cell Sci., March 15, 2006; 119(6): 1043 - 1052.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
D. H. Freed, R. H. Cunnington, A. L. Dangerfield, J. S. Sutton, and I. M.C. Dixon
Emerging evidence for the role of cardiotrophin-1 in cardiac repair in the infarcted heart
Cardiovasc Res, March 1, 2005; 65(4): 782 - 792.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
X.-M. Yang, J. B. Proctor, L. Cui, T. Krieg, J. M. Downey, and M. V. Cohen
Multiple, brief coronary occlusions during early reperfusion protect rabbit hearts by targeting cell signaling pathways
J. Am. Coll. Cardiol., September 1, 2004; 44(5): 1103 - 1110.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
R. Toh, S. Kawashima, M. Kawai, T. Sakoda, T. Ueyama, S. Satomi-Kobayashi, S. Hirayama, and M. Yokoyama
Transplantation of cardiotrophin-1-expressing myoblasts to the left ventricular wall alleviates the transition from compensatory hypertrophy to congestive heart failure in Dahl salt-sensitive hypertensive rats
J. Am. Coll. Cardiol., June 16, 2004; 43(12): 2337 - 2347.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
D. J Hausenloy and D. M Yellon
New directions for protecting the heart against ischaemia-reperfusion injury: targeting the Reperfusion Injury Salvage Kinase (RISK)-pathway
Cardiovasc Res, February 15, 2004; 61(3): 448 - 460.
[Abstract] [Full Text] [PDF]


Home page
EndocrinologyHome page
E. A. Woodcock
Unc-II and Unc-III Are Cardioprotective against Ischemia Reperfusion Injury: An Essential Endogenous Cardioprotective Role for CRFR2 in the Murine Heart
Endocrinology, January 1, 2004; 145(1): 21 - 23.
[Full Text] [PDF]


Home page
EndocrinologyHome page
B. K. Brar, A. K. Jonassen, E. M. Egorina, A. Chen, A. Negro, M. H. Perrin, O. D. Mjos, D. S. Latchman, K.-F. Lee, and W. Vale
Urocortin-II and Urocortin-III Are Cardioprotective against Ischemia Reperfusion Injury: An Essential Endogenous Cardioprotective Role for Corticotropin Releasing Factor Receptor Type 2 in the Murine Heart
Endocrinology, January 1, 2004; 145(1): 24 - 35.
[Abstract] [Full Text] [PDF]



Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.